Porres, D
Pfister, D
Thissen, A
Kuru, T H
Zugor, V
Buettner, R
Knuechel, R
Verburg, F A
Heidenreich, A
Article History
Received: 29 June 2016
Revised: 16 August 2016
Accepted: 11 September 2016
First Online: 8 November 2016
Competing interests
: D Porres has received consultancy fees, payment for speaker bureaus and travel support from Astellas, Bayer, Ipsen and Janssen and Novartis. D Pfister has received consultancy fees and payment for speaker bureaus from Astellas, Ipsen, Sanofi and Janssen. FAV is a consultant to Bayer and Genzyme. AH has received consultancy fees and payment for speaker bureaus from Amgen, Janssen, Ipsen, Sanofi and Takeda (for whom he is also a board member); research and travel support from Astellas; and a research grant from Sanofi. The remaining authors declare no conflicts of interest.